The CSL (ASX:CSL) share price has gained 14% in the last 6 months

Here's what's been driving the CSL share price lately.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has gained 14.36% over the last 6 months, despite limited news having been released by the company.

However, the period has been a busy one for CSL, as detailed in its financial year 2021 results which dropped last week.

Right now, the CSL share price is $306.91, having gained 0.26% today.

Let's take a closer look at what CSL has been up to over the past 6 months.

The 6 months just gone for CSL

The CSL share price is currently a whopping 14% higher than it was exactly 6 months ago, despite the company having been relatively quiet. Indeed, the most exciting news from CSL was also its most recent.

CSL released its full-year report to the market on Wednesday last week. Over the financial year 2021, CSL's revenue increased 9.6% and its profit after tax boosted 10% higher.

Additionally, the company increased its final dividend by 10% to US$2.22 per share.

While the CSL share price initially fell 1.4% on its FY21 results, it has gained since 4.5%.

The only other time the ASX heard price-sensitive news from CSL during the last 6 months was in May when the company announced it was to acquire the rights for etranacogene dezaparvovec (AMT-061), a late-stage haemophilia B treatment.

The deal saw CSL pay Uniqure NV US$450 million for the rights. CSL also agreed to provide milestone royalty payments to Uniqure.

Additionally, as The Motley Fool Australia recently reported, CSL's gains could have been helped along by its candidacy in potentially producing mRNA vaccines in Australia, or the Australian dollar's strength against that of the US.

CSL share price snapshot

The last 6 months have seen the CSL share price perform a strong upturn.

Right now, it is 8.3% higher than it was at the start of 2021. It is also 3.8% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Prediction: CSL shares could surpass $265 in 2026

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn.

Read more »